Regenxbio Inc (RGNX)
9.75
+0.57
(+6.21%)
USD |
NASDAQ |
Nov 22, 13:35
Regenxbio Total Assets (Quarterly): 519.11M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 519.11M |
| June 30, 2024 | 569.38M |
| March 31, 2024 | 629.22M |
| December 31, 2023 | 573.97M |
| September 30, 2023 | 633.79M |
| June 30, 2023 | 682.46M |
| March 31, 2023 | 747.83M |
| December 31, 2022 | 833.27M |
| September 30, 2022 | 883.79M |
| June 30, 2022 | 953.44M |
| March 31, 2022 | 1.025B |
| December 31, 2021 | 1.114B |
| September 30, 2021 | 800.40M |
| June 30, 2021 | 836.40M |
| March 31, 2021 | 879.44M |
| December 31, 2020 | 708.16M |
| September 30, 2020 | 541.17M |
| June 30, 2020 | 449.74M |
| March 31, 2020 | 463.94M |
| December 31, 2019 | 497.91M |
| Date | Value |
|---|---|
| September 30, 2019 | 509.24M |
| June 30, 2019 | 529.14M |
| March 31, 2019 | 519.03M |
| December 31, 2018 | 543.81M |
| September 30, 2018 | 514.98M |
| June 30, 2018 | 335.99M |
| March 31, 2018 | 317.22M |
| December 31, 2017 | 198.68M |
| September 30, 2017 | 209.26M |
| June 30, 2017 | 224.38M |
| March 31, 2017 | 224.13M |
| December 31, 2016 | 172.73M |
| September 30, 2016 | 195.98M |
| June 30, 2016 | 206.07M |
| March 31, 2016 | 214.98M |
| December 31, 2015 | 221.38M |
| September 30, 2015 | 227.31M |
| June 30, 2015 | 88.80M |
| December 31, 2014 | 3.491M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
449.74M
Minimum
Jun 2020
1.114B
Maximum
Dec 2021
717.13M
Average
695.31M
Median
Total Assets (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 772.01M |
| EyePoint Pharmaceuticals Inc | 300.92M |
| Cassava Sciences Inc | 223.75M |
| Vertex Pharmaceuticals Inc | 22.24B |
| Sarepta Therapeutics Inc | 3.600B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 217.70M |
| Shareholders Equity (Quarterly) | 301.42M |
| Current Ratio | 3.051 |